{"id":67946,"date":"2025-10-03T07:00:43","date_gmt":"2025-10-03T07:00:43","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=67946"},"modified":"2026-04-30T10:23:26","modified_gmt":"2026-04-30T10:23:26","slug":"bdenza","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/bdenza\/","title":{"rendered":"Bdenza"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">&#9889; Quick Answer &mdash; What is Bdenza?<\/h3>\n<p style=\"margin:0;\"><strong>Bdenza<\/strong> is an oral tablet from Beacon Pharmaceuticals containing <strong>enzalutamide 40 mg<\/strong> \u2014 un <strong>second-generation androgen-receptor signalling inhibitor<\/strong>. Utilizat\u0103 pentru <strong>metastatic castration-resistant prostate cancer (mCRPC)<\/strong>, <strong>non-metastatic CRPC<\/strong> \u0219i <strong>metastatic hormone-sensitive prostate cancer<\/strong>. Standard dose: <strong>160 mg once daily (4 &times; 40 mg tablets)<\/strong>, with or without food. More potent than first-generation anti-androgens (bicalutamide, flutamide) and active in castration-resistant disease where they fail. <strong>Seizure risk &mdash; avoid in patients with history of seizures.<\/strong> Other key risks: hypertension, fatigue, falls\/fractures, cognitive effects, posterior reversible encephalopathy syndrome (rare). Continue concurrent LHRH agonist throughout treatment. Mandatory monitoring: BP at baseline + at each visit, periodic LFTs + FBC.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<h2 class=\"wp-block-heading\">What Is Bdenza?<\/h2>\n<p>Bdenza is an oral tablet from Beacon Pharmaceuticals containing <strong>enzalutamide 40 mg<\/strong>. Enzalutamide is a <strong>second-generation androgen-receptor (AR) signalling inhibitor<\/strong> &mdash; mechanistically distinct from the first-generation anti-androgens (bicalutamide, flutamide). It is licensed for: <strong>metastatic castration-resistant prostate cancer (mCRPC)<\/strong> in chemotherapy-na&iuml;ve and post-docetaxel patients; <strong>non-metastatic CRPC<\/strong> with rapidly rising PSA; and <strong>metastatic castration-sensitive prostate cancer (mHSPC)<\/strong> with concurrent ADT.<\/p>\n<h2 class=\"wp-block-heading\">How Does Bdenza Work?<\/h2>\n<p>Enzalutamide is a triple-action AR signalling inhibitor:<\/p>\n<ul>\n<li><strong>Competitive AR binding<\/strong> with much higher affinity than first-generation anti-androgens.<\/li>\n<li><strong>Inhibits AR nuclear translocation<\/strong> &mdash; even when bound by androgen, prevents the receptor from entering the nucleus.<\/li>\n<li><strong>Inhibits AR-DNA binding<\/strong> &mdash; even if AR enters the nucleus, prevents binding to androgen-response elements on target genes.<\/li>\n<\/ul>\n<p>This triple mechanism makes enzalutamide active in <strong>castration-resistant prostate cancer<\/strong>, where AR overexpression and AR-splice variants make first-generation anti-androgens ineffective.<\/p>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>Metastatic castration-resistant prostate cancer (mCRPC)<\/strong> &mdash; chemotherapy-na&iuml;ve (PREVAIL) and post-docetaxel (AFFIRM)<\/li>\n<li><strong>Non-metastatic CRPC with PSA doubling time &lt; 10 months<\/strong> (PROSPER)<\/li>\n<li><strong>Metastatic hormone-sensitive prostate cancer (mHSPC)<\/strong> with ADT (ARCHES, ENZAMET)<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Bdenza Dosage and How to Take<\/h2>\n<p>Doza standard: <strong>160 mg once daily (4 &times; 40 mg tablets) at the same time each day<\/strong>, cu sau f\u0103r\u0103 m\u00e2ncare.<\/p>\n<ol>\n<li>Swallow tablets whole with water. Do NOT chew, dissolve or split.<\/li>\n<li>Continue concurrent LHRH agonist therapy throughout enzalutamide treatment unless surgically castrated.<\/li>\n<li><strong>Monitorizare obligatorie:<\/strong> blood pressure at baseline and each clinic visit; LFTs and FBC periodically; PSA every 3 months.<\/li>\n<li><strong>Falls and fracture prevention:<\/strong> elderly patients have increased fall and fracture risk on enzalutamide. Bone health assessment, calcium + vitamin D, consider bisphosphonate.<\/li>\n<li><strong>Dose modifications<\/strong> for moderate hepatic impairment, severe adverse events, or grade &ge; 3 toxicity: reduce to 80 or 120 mg\/day under specialist guidance.<\/li>\n<li>Nu \u00eentrerupe\u021bi f\u0103r\u0103 instruc\u021biuni de la oncolog.<\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Side Effects of Bdenza<\/h2>\n<p><strong>Frecvente:<\/strong> fatigue (the dominant side effect), hot flushes, hypertension, fall and fracture risk (elderly), arthralgia, headache, dizziness, decreased weight, anxiety, insomnia.<\/p>\n<p><strong>Important:<\/strong><\/p>\n<ul>\n<li><strong>Seizures (&lt; 1% in trials)<\/strong> &mdash; lower seizure threshold; avoid in any patient with seizure history or on drugs lowering seizure threshold<\/li>\n<li>Cognitive effects: memory difficulties, concentration impairment<\/li>\n<li>Hypertension &mdash; new-onset or worsening; treat aggressively<\/li>\n<li>Posterior reversible encephalopathy syndrome (PRES) &mdash; rare but documented; new-onset severe headache, confusion, vision changes, seizures<\/li>\n<li>Hepatotoxicity (mild LFT rises common; severe rare)<\/li>\n<li>Neutropenia, anaemia<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Seizure history (any type):<\/strong> avoid enzalutamide. If essential, specialist neurology + oncology supervision.<\/li>\n<li><strong>Drugs that lower seizure threshold<\/strong> (bupropion, clozapine, tramadol, fluoroquinolones, theophylline): caution.<\/li>\n<li><strong>Falls and fracture risk:<\/strong> bone health assessment, supportive care.<\/li>\n<li><strong>Hipertensiune arterial\u0103:<\/strong> baseline + ongoing BP monitoring.<\/li>\n<li><strong>Insuficien\u021b\u0103 hepatic\u0103 sever\u0103 (Child-Pugh C):<\/strong> nu este recomandat.<\/li>\n<li><strong>PRES symptoms:<\/strong> new severe headache, vision change, confusion &mdash; stop and seek same-day review.<\/li>\n<li><strong>Pregnancy \/ fertility:<\/strong> male-only indication. Use condom + contraception with female partners of childbearing potential during treatment + 3 months after.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP2C8 inhibitors (gemfibrozil)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Raise enzalutamide levels &mdash; toxicity risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Reduce enzalutamide to 80 mg\/day if combination unavoidable.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Strong CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, St John&#39;s wort)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Lower enzalutamide levels &mdash; treatment failure<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid. If unavoidable, increase to 240 mg\/day under specialist guidance.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin and other CYP2C9 \/ CYP3A4 substrates with narrow therapeutic index<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Enzalutamide is a strong CYP3A4 inducer &mdash; lowers many drug levels<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Switch warfarin to a DOAC (apixaban, edoxaban) or monitor INR weekly.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Increased seizure risk<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Avoid where possible.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Agoni\u0219ti LHRH (goserelin, leuprorelin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Standard background therapy<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Continue throughout enzalutamide treatment.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>Store at room temperature, 15&ndash;30&deg;C.<\/li>\n<li>P\u0103stra\u021bi la distan\u021b\u0103 de copii, femei \u00een v\u00e2rst\u0103 fertil\u0103 \u0219i animale de companie.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bicalumutide\/\"><strong>Bicalumutid\u0103 (bicalutamid\u0103 50 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytomid\/\"><strong>Cytomid (flutamid\u0103 250 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Medicamente Anticanceroase Asem\u0103n\u0103toare<\/h3>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bicalumutide\/\">Bicalumutid\u0103 (bicalutamid\u0103 50 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytomid\/\">Cytomid (flutamid\u0103 250 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/endace\/\">Endace (megestrol 40\/160 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/tamilong\/\">Tamilong (tamoxifen 10\/20 mg)<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/votrient\/\">Votrient (pazopanib 200\/400 mg)<\/a><\/li>\n<\/ul>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">How is Bdenza different from bicalutamide or flutamide?<\/h3>\n<p>Enzalutamide is a <strong>second-generation<\/strong> AR signalling inhibitor with three mechanisms (AR binding + AR nuclear translocation block + AR-DNA binding block) versus the single mechanism of first-generation drugs. The clinical implication: <strong>enzalutamide works in castration-resistant disease<\/strong> where bicalutamide and flutamide have failed. It is also more potent and produces deeper PSA responses but with more cognitive side effects, hypertension and fall risk.<\/p>\n<h3 class=\"wp-block-heading\">Why is seizure history a contraindication?<\/h3>\n<p>Enzalutamide crosses the blood-brain barrier and lowers seizure threshold. In trials, seizure incidence was &lt; 1% but increased in patients with predisposing factors. Avoid enzalutamide in any patient with prior seizure (any type), brain metastases, or concurrent drugs lowering seizure threshold (bupropion, tramadol, clozapine, fluoroquinolones, theophylline). If enzalutamide is essential in such a patient, neurology and oncology specialists must agree on the risk-benefit.<\/p>\n<h3 class=\"wp-block-heading\">Will I have to stop ADT (LHRH agonist) when I start Bdenza?<\/h3>\n<p>No &mdash; continue your LHRH agonist (goserelin, leuprorelin, etc.) throughout enzalutamide treatment. The combination of background castration + AR signalling inhibition is essential. Stopping the LHRH agonist allows testosterone to recover, which can defeat enzalutamide&#39;s effect.<\/p>\n<h3 class=\"wp-block-heading\">Why is fatigue so common on Bdenza?<\/h3>\n<p>Fatigue is the most common and clinically significant side effect &mdash; affecting around 35% of patients in trials. The cause is multifactorial: profound androgen deprivation, possible direct CNS effects, anaemia. Manage with structured exercise (counterintuitively effective), good sleep hygiene, screening and treatment of anaemia, and consideration of dose reduction (160 &rarr; 120 mg\/day) if intolerable.<\/p>\n<h3 class=\"wp-block-heading\">What is PRES and how do I recognise it?<\/h3>\n<p>Posterior reversible encephalopathy syndrome (PRES) is a rare but documented enzalutamide complication characterised by <strong>severe headache, confusion, visual changes (cortical blindness), seizures and altered consciousness<\/strong>. Stop enzalutamide immediately and seek same-day medical review for any of these symptoms. Most cases resolve with drug discontinuation but timely recognition prevents permanent neurological injury.<\/p>\n<h3 class=\"wp-block-heading\">Are there many drug interactions I need to worry about?<\/h3>\n<p>Yes &mdash; enzalutamide is a <strong>strong CYP3A4 inducer<\/strong> and lowers blood levels of many co-prescribed drugs. The most clinically important: <strong>warfarin<\/strong> (switch to a DOAC or check INR weekly), <strong>direct oral anticoagulants<\/strong> (specialist review), some statins, some antihypertensives, opioids, some antiepileptics. Tell every doctor you are on enzalutamide.<\/p>\n<h3 class=\"wp-block-heading\">Can I drive on Bdenza?<\/h3>\n<p>Caution &mdash; fatigue, dizziness and (rarely) seizures may impair driving. Most patients adapt and drive safely after the first few weeks. Avoid driving or operating machinery if you experience significant fatigue, dizziness, or any cognitive symptoms.<\/p>\n<h3 class=\"wp-block-heading\">Bdenza vs abiraterone &mdash; which is better?<\/h3>\n<p>Both are second-line options after first-generation anti-androgen failure. Head-to-head data is limited; choice depends on side-effect preference and comorbidities. <strong>Enzalutamide:<\/strong> more fatigue, cognitive effects, hypertension, fall risk; no steroid co-prescription needed. <strong>Abiraterone:<\/strong> requires concurrent prednisone 5 mg twice daily; more hypertension and fluid retention; may worsen diabetes control. Discuss with your oncologist.<\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Slows cancer progression<br \/>\n\u2705 Reduces tumor growth<br \/>\n\u2705 Improves survival outcomes<br \/>\n\u2705 Supports prostate treatment<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te calitatea vie\u021bii<\/p>\n<p><strong>Bdenza<\/strong> con\u021bine <strong>Enzalutamide<\/strong> 40 mg.<\/p>","protected":false},"featured_media":67947,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[3595],"product_tag":[5422,5423],"class_list":{"0":"post-67946","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_tag-bdenza","8":"product_tag-enzalutamide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/67946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=67946"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/67947"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=67946"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=67946"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=67946"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=67946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}